Mandate

The European Investment Bank has signed a EUR 47 million financing agreement with Swedish innovative battery technology company Nilar.

October 05, 2020 Banking and Finance

Vinge has acted as European Investment Bank’s (the EIB) counsel in the financing of the battery technology company Nilar International AB (Nilar).

The financing is supported by the InnovFin Energy Demonstration Projects of the European Commission which is a venture financing instrument designated to support innovative clean energy projects in the fields of e.g. renewable energy and energy storage. The aim of the programme is to bridge the gap from demonstration to commercialisation and thus contribute to the deployment of the next generation of innovative low-carbon energy technologies. A link to EIB’s press release may be found here.

Nilar is the globally leading manufacturer of advanced Hydride® batteries (NiMH) for energy storage. Its solutions offer unique safety benefits and are environment-friendly. With production based on 100 percent renewable energy at the manufacturing plant in Sweden, Nilar is revolutionising energy and power supply technology, and advancing the technique of automated battery production. Read more at Nilar’s website.

Vinge’s team included Johan Larsson, Albert Wållgren, Ludvig Wettergren and Viktor Lennartsson.

 

Related

Vinge advises OsteoCentric on the public offer for Integrum

OsteoCentric Oncology and Bone Anchored Prostheses, LLC, a subsidiary of OsteoCentric Technologies, Inc., has made a public offer for all shares in Integrum AB (publ). The offer values all shares in Integrum at approximately SEK 939 million.
July 23, 2025

Vinge advises Investor on its co-investment in the SEK 55 billion public offer for Fortnox led by EQT X

Vinge advises Investor AB (publ) (“Investor”) on its co-investment in the public offer for Fortnox AB (publ) (“Fortnox”) led by EQT X together with First Kraft AB (owned by Olof Hallrup), acting through Omega II AB (“Omega II”). Fortnox offers vital software infrastructure to small and medium-sized companies in Sweden with a track record of profitable growth.
July 22, 2025

Vinge advises Cantargia in connection with the sale of immunology program CAN10

Vinge advises Cantargia AB (publ) in connection with the sale of its early-clinical stage IL1RAP immunology program CAN10 to the Japanese healthcare company Otsuka Pharmaceutical.
July 21, 2025